Qynapse

Qynapse is a medical software company specializing in AI-powered neuroimaging analysis for central nervous system (CNS) diseases. The company develops advanced algorithms and software platforms that analyze MRI brain scans to provide automated biomarkers, diagnostic support, and disease monitoring capabilities for conditions including Alzheimer's disease, multiple sclerosis, and Parkinson's disease. QyScore® is Qynapse's flagship FDA-cleared (Class II) and CE-marked (Class IIa) software product designed for automatic labeling, visualization, and volumetric quantification of brain structures and lesions from MR images. The software provides volumetric data compared to reference percentile datasets and is intended to support clinicians in CNS disease diagnosis and monitoring. QyPredict® is a research-use-only platform combining genomics, biofluids, neuroimaging, cognitive endpoints, and activity measures to assess CNS disease trajectory. Qynapse addresses a critical clinical need: current CNS disease misdiagnosis rates reach approximately 30%, and the company reports diagnostic accuracy improvement from 66–70% to over 90%. The company serves healthcare providers, pharmaceutical researchers, payers, and patients/caregivers. Products are built on proprietary technology incorporating 20 algorithms and the company's proprietary normative dataset of over 10,000 brain scan images. Regulatory approvals include FDA clearance and CE marking; expansion into additional global markets is underway. The company's clinical advisory board includes leading neurology and radiology experts.